Axsome Unveils Commercial Plans for FDA-Approved AUVELITY Alzheimer’s Agitation Treatment
Axsome Therapeutics is hosting a virtual investor event today at 8:00 AM Eastern to discuss the FDA’s recent approval of AUVELITY for agitation associated with dementia due to Alzheimer’s disease. Management and Dr. Jeffrey Cummings will review the treatment’s NMDA and sigma-1 receptor mechanism and outline anticipated commercial plans.
1. Virtual Investor Event
Axsome Therapeutics will host a virtual investor event and conference call today at 8:00 AM Eastern to review the FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer’s disease. Dr. Jeffrey Cummings and the Axsome management team will present scientific insights and commercial outlook.
2. FDA Approval Details
AUVELITY received FDA approval for adults with agitation associated with dementia due to Alzheimer’s disease, marking the first-in-class NMDA receptor antagonist and sigma-1 agonist indicated for this neuropsychiatric condition. The approval follows AUVELITY’s initial 2022 clearance for major depressive disorder and underscores its distinct receptor-targeting mechanism.
3. Commercial Strategy and Patent
During the event, management will outline anticipated U.S. launch timing, marketing initiatives and sales projections for AUVELITY in the Alzheimer’s agitation market. The company highlighted a patent estate protecting AUVELITY until at least 2043, supporting long-term exclusivity.